NOGG指南中极高骨折风险干预阈值的评估
本研究基于NOGG混合评估模型,在模拟的英国50岁以上女性队列中检验极高骨折风险干预阈值。结果显示采用1.6倍现有干预阈值作为上限时,10%女性被归为极高风险,与合成代谢药物试验入组人群风险水平相当。
要点
- NOGG混合模型以1.6倍现有干预阈值为上限,将10%的50岁以上女性归为极高骨折风险。
- IOF/ESCEO标准下56%女性被归为极高风险,而年龄特异性阈值下为36%。
- romosozumab或特立帕肽试验中多数参与者属于极高风险类别。
核心结论
- 基于FRAX的NOGG混合模型极高风险标准仅将10%的50岁以上女性归入最高风险层。
研究设计与样本
- 研究基于NOGG混合评估模型,在模拟的英国50岁以上女性横断面队列中检验干预阈值,基线特征分布参照FRAX队列。
主要发现
- 采用IOF/ESCEO标准的上限干预阈值时,56%的50岁以上女性被归为极高风险。
- 采用IOF/ESCEO标准且所有年龄使用年龄特异性干预阈值时,36%的50岁以上女性被归为极高风险。
- 采用现有干预阈值的1.6倍作为上限干预阈值时,10%的50岁以上女性被归为极高风险。
- 3期研究数据显示,多数暴露于romosozumab或特立帕肽的试验参与者属于极高风险类别。
关键数值与推荐
- NOGG混合模型极高风险上限干预阈值为现有干预阈值的1.6倍,对应10%的50岁以上女性被归为极高风险。
- IOF/ESCEO标准上限干预阈值对应56%的50岁以上女性被归为极高风险。
- IOF/ESCEO标准年龄特异性干预阈值对应36%的50岁以上女性被归为极高风险。
临床怎么用
- 临床可参考NOGG混合模型以1.6倍现有干预阈值为上限识别极高骨折风险患者,该阈值下风险水平与合成代谢药物试验人群相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The National Osteoporosis Guideline Group (NOGG) has developed intervention thresholds based on FRAX® to characterise patients at high and very high risk of fracture. INTRODUCTION: Guidelines for the assessment of fracture risk have begun to categorise patients eligible for treatment into high and very high risk of fracture to inform choice of therapeutic approach. The aim of the present study was to develop intervention thresholds based on the hybrid assessment model of NOGG. METHODS: We examined the impact of intervention thresholds in a simulated cross-sectional cohort of women age 50 years or more from the UK with the distribution of baseline characteristics based on that in the FRAX cohorts. The prevalence of very high risk using the hybrid model was compared with age-dependent thresholds used by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (IOF/ESCEO). The appropriateness of thresholds was tested based on the populations treated with anabolic agents. RESULTS: With an upper intervention threshold using the IOF/ESCEO criteria, 56% of women age 50 years or more would be characterised at very high risk. This compares with 36% using the IOF/ESCEO criteria and an age-specific intervention threshold over all ages. With an upper intervention threshold of 1.6 times the pre-existing intervention threshold, 10% of women age 50 years or more would be characterised at very high risk. The data from phase 3 studies indicate that most trial participants exposed to romosozumab or teriparatide would fall into the very high-risk category. CONCLUSIONS: Proposals for FRAX-based criteria for very high risk for the NOGG hybrid model categorise a small proportion of women age 50 years or more (10%) in this highest risk stratum. The level of risk identified was comparable to that of women enrolled in trials of anabolic agents.
引用
- Kanis JA, Johansson H, Harvey NC, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int. 2021. PMID: 33813622. doi:10.1007/s00198-021-05942-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。